Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal
July 17, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, July 17, 2023 (GLOBE NEWSWIRE) -- -Detailed results from house dust mite trial published in Clinical and Translational Allergy-Study demonstrates statistically significant...
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
July 05, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform in the regeneration of damaged heart tissue Altamira...
Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model
March 22, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, March 22, 2023 (GLOBE NEWSWIRE) -- Preprint of results from animal study shows restriction of tumor growth in mice treated with ZBTB46 mRNA nanoparticles based on Altamira’s...
Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
February 27, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Altamira’s ability to target different KRAS mutations with a single polyvalent siRNA sequence illustrates versatility and potential of RNA...
Altamira Therapeutics Provides Business Update
January 27, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Process for divestiture / partnering of legacy assets continuesStrong data from Bentrio® NASAR study reinforces its therapeutic benefit for...
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
January 24, 2023 08:17 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Jan. 24, 2023 (GLOBE NEWSWIRE) -- Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant improvement with Bentrio® in nasal...
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th
January 10, 2023 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Company COO Dr. Pañeda will discuss SemaPhoreTM platform’s functionality with mRNA, and:Peptide-based platform for extrahepatic deliveryThe...
Altamira Therapeutics Provides Year-End 2022 Business Update
December 19, 2022 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Dec. 19, 2022 (GLOBE NEWSWIRE) --Altamira Therapeutics Provides Year-End 2022 Business Update Strategic BentrioTM partnering or divestiture process enters decisive phasePartnering...
Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results
November 30, 2022 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- BentrioTM nasal spray launched in Hong Kong by partner Nuance Pharma to help protect against viruses and allergensCOVAMID trial with Bentrio in...
Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
November 30, 2022 08:07 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Initiative is Nuance’s first step in penetrating Chinese market with BentrioTMDensely populated Hong Kong (7.3 million) remains negatively...